Nautilus Biotechnology Announces Board Restructuring

An update from Nautilus Biotechnolgy ( (NAUT) ) is now available.

Nautilus Biotechnology, Inc. held its 2025 annual meeting of stockholders on June 20, 2025, where 99,716,163 shares were represented. During the meeting, Sujal Patel and Matthew McIlwain were elected as Class I directors, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, the company announced the resignation of former directors Vijay Pande and Michael Altman, and the restructuring of the board to consist of seven directorships.

The most recent analyst rating on (NAUT) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Nautilus Biotechnolgy stock, see the NAUT Stock Forecast page.

Spark’s Take on NAUT Stock

According to Spark, TipRanks’ AI Analyst, NAUT is a Neutral.

Nautilus Biotechnology’s score reflects its early-stage status with high operational losses and zero revenue, typical for biotech firms focused on R&D. While its strong cash reserves and low leverage offer some stability, persistent losses and slow pharma partnerships pose significant risks. Technical indicators suggest a bearish trend, but the earnings call highlighted positive advancements in proteomics and cost efficiencies, offering a cautiously optimistic outlook.

To see Spark’s full report on NAUT stock, click here.

More about Nautilus Biotechnolgy

Nautilus Biotechnology, Inc. operates in the biotechnology industry, focusing on developing advanced proteomics platforms to analyze and understand the human proteome.

Average Trading Volume: 191,636

Technical Sentiment Signal: Sell

Current Market Cap: $90.16M

For an in-depth examination of NAUT stock, go to TipRanks’ Overview page.